Breaking technological barriers

Avista’s Innovation platform addresses the most critical barriers to the development of gene therapies by reimagining what’s possible. Our Innovation programs combine structural biology, protein design and deep clinical expertise to pioneer new solutions to the field's toughest technological challenges.

Avista’s Innovation platform is tackling the most critical technological barriers to gene therapy development and patient access:

Avista Innovation Program 1: Large gene delivery

The packaging limit of AAV vectors leaves many large therapeutic genes and genetic tools —and the patients who need them— behind. Avista is developing novel AAV systems that will enable safe and effective delivery of large payloads.

A digital illustration of an AAV with a large payload.

Avista Innovation Program 2: AAV manufacturing

AAV production is complex and expensive, limiting which patients can access life-changing therapies and which diseases are worth pursuing. Avista is pioneering new AAV manufacturing strategies from the ground up to enable reliable, scalable, and accessible therapies.

A digital illustration of AAV packaging.

Avista Innovation Program 3: Functionalized AAVs

Targeting capsids to the correct cell types is critical for the success and safety of a gene therapy. Avista functionalizes capsids using our modular and buildable AAV decoration system.

A digital illustration of a functionalized AAV capsid.

Avista Innovation Program 4: Beyond AAV

Avista is thinking beyond AAV. We are working to create new delivery vectors that do all the things that are needed, and none of the things that aren’t.

A digital illustration of a large viral vector.